Pharmacologic Substance
eltrombopag
Brand Names:
Promacta
May Treat:
Anemia, Aplastic; Purpura, Thrombocytopenic, Idiopathic
More Information:
ChemID; DrugBank; DailyMed; DrugInfo; PDR
Definitions related to eltrombopag:
  • An orally active thrombopoietin receptor agonist with megakaryopoiesis stimulating activity. Eltrombopag binds to and stimulates the platelet thrombopoietin receptor (TPO-R or CD110), a member of the hematopoietin receptor superfamily. Activation of TPO-R leads to the proliferation and differentiation of megakaryocytes, thereby increasing the production of blood platelets.
    NCI Thesaurus
    U.S. National Cancer Institute, 2021
  • The active ingredient in a drug used to treat chronic immune thrombocytopenic purpura (a condition in which platelets are destroyed by the immune system). It causes more platelets to be made in the bone marrow. It is also being studied in the treatment of low platelet counts caused by chemotherapy. It is a type of thrombopoietin receptor agonist.
    NCI Dictionary of Cancer Terms
    U.S. National Cancer Institute, 2021
Try this search on: Farlex, Merriam-Webster, Oxford Dictionary, or Wordnik

This content should not be used in place of medically-reviewed decision support reference material or professional medical advice. Some terms may have alternate or updated definitions not reflected in this set. The definitions on this page should not be considered complete or up to date.